Stockscreener 앱 받기
0.7224
4.62%
-0.035
시간 외 거래:
.72
-0.0024
-0.33%
전일 마감가:
$0.7574
열려 있는:
$0.7792
하루 거래량:
3.69M
Relative Volume:
0.81
시가총액:
$156.76M
수익:
-
순이익/손실:
$-90.60M
주가수익비율:
-1.1525
EPS:
-0.6268
순현금흐름:
$-68.88M
1주 성능:
-12.17%
1개월 성능:
+20.00%
6개월 성능:
-51.52%
1년 성능:
+10.51%
1일 변동 폭
$0.721
$0.804
1주일 범위
$0.718
$0.8315
52주 변동 폭
$0.36
$2.35
Tenaya Therapeutics Inc Stock (TNYA) Company Profile
명칭
Tenaya Therapeutics Inc
전화
415-865-2066
주소
171 OYSTER POINT BLVD., SUITE 500, SOUTH SAN FRANCISCO
Compare TNYA vs VRTX, REGN, ALNY, ARGX, INSM
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
TNYA
Tenaya Therapeutics Inc
|
0.7224 | 164.35M | 0 | -90.60M | -68.88M | -0.6268 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 113.96B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 78.41B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 40.85B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 42.05B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 29.99B | 606.42M | -1.28B | -997.58M | -6.403 |
Tenaya Therapeutics Inc Stock (TNYA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-06-10 | 개시 | William Blair | Outperform |
| 2023-11-30 | 개시 | Leerink Partners | Outperform |
| 2022-06-15 | 개시 | H.C. Wainwright | Buy |
Tenaya Therapeutics Inc 주식(TNYA)의 최신 뉴스
William Blair analysts confident on Tenaya Therapeutics (TNYA) product pipeline - MSN
William Blair Analysts Confident on Tenaya Therapeutics (TNYA) Product Pipeline - Yahoo Finance
Alnylam’s research pact worth up to $1.1B sends Tenaya higher - MSN
Tenaya Therapeutics, Inc. (TNYA) reports Q4 EPS of (12c), in line with consensus - MSN
Tenaya Therapeutics, Inc. (TNYA) Reports Q4 EPS of (12c), In Line with Consensus - Insider Monkey
TNYA pulls back after hours following significant $1.13B deal-spurred rally - MSN
symbol__ Stock Quote Price and Forecast - CNN
Tenaya Therapeutics, Inc. (NASDAQ:TNYA) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Tenaya Therapeutics (NASDAQ:TNYA) Rating Lowered to "Sell" at Wall Street Zen - MarketBeat
How TN-301 Progress And Alnylam Deal At Tenaya Therapeutics (TNYA) Has Changed Its Investment Story - simplywall.st
What is Lifesci Capital's Estimate for TNYA Q1 Earnings? - MarketBeat
Outperform Maintained on Tenaya Therapeutics (TNYA) by Leerink and William Blair March 2026 - Meyka
Tenaya Therapeutics (TNYA) Valuation After TN-301 Data And New Alnylam Collaboration - simplywall.st
William Blair reiterates Outperform on Tenaya Therapeutics stock - Investing.com Australia
William Blair reiterates Outperform on Tenaya Therapeutics stock By Investing.com - Investing.com South Africa
Leerink Partners reiterates Outperform on Tenaya stock at $2 - Investing.com UK
Chardan Capital Reiterates Buy Rating for Tenaya Therapeutics (NASDAQ:TNYA) - MarketBeat
Tenaya Therapeutics Reports Promising 2025 Results, Advances Gene Therapy Programs, and Extends Cash Runway Into 2027 - Minichart
Tenaya Therapeutics (TNYA) Is Up 47.7% After Positive TN-301 DMD Data And Alnylam Deal - Yahoo Finance
Tenaya Therapeutics: Advancing Genetic Medicines and Small Molecule Therapies for Heart Disease Treatment - Minichart
Tenaya Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update - Bitget
Tenaya Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Tenaya Therapeutics' Q4 net loss narrows, extends cash runway into H2 2027 - TradingView
Tenaya Therapeutics (NASDAQ:TNYA) Issues Earnings Results, Meets Expectations - MarketBeat
Tenaya Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
TNYA: Clinical progress, Alnylam deal, and financing extend cash runway into 2027 - TradingView
Tenaya Therapeutics (NASDAQ: TNYA) narrows 2025 loss and extends cash runway to 2027 - Stock Titan
Q4 and 2025 results drive business momentum, Tenaya Therapeutics outlines - Traders Union
BRIEF-Tenaya Therapeutics Q4 Net Income USD -20.175 Million Vs. IBES Estimate USD -22 Million - TradingView
Heart gene therapy data and $1.1B Alnylam deal help Tenaya fund work to 2027 - Stock Titan
Tenaya Therapeutics Soars with Major Collaboration Deal - timothysykes.com
Tenaya Therapeutics Reports TN-301 Outperforms Givinostat in Enhancing Muscle Function and Addressing DMD Cardiomyopathy - Quiver Quantitative
Experimental drug TN-301 restores muscle strength in Duchenne mice - Stock Titan
Tenaya Therapeutics Presents Preclinical Data at MDA 2026 - GlobeNewswire
Tenaya Therapeutics Presents Preclinical Data at MDA 2026 Highlighting TN-301's Potential to Correct Skeletal and Cardiac Muscle Decline in Duchenne Muscular Dystrophy - Bitget
Assessing Alnylam Pharmaceuticals (ALNY) Valuation After New Cardiovascular Partnership With Tenaya Therapeutics - Sahm
Leerink Partners Global Biopharma Conference 2026: TEVA, CYTK, IMRX, TNYA And More Set To Present - RTTNews
Morgan Stanley reduces PT on Tenaya Therapeutics (TNYA), keeps constructive stance on US small- to mid-cap biotech - MSN
Tenaya Therapeutics, Inc.Common Stock (NQ: TNYA - The Chronicle-Journal
Tenaya Therapeutics announces orderly board leadership transition - MSN
Lifesci Capital Upgrades Tenaya Therapeutics (NASDAQ:TNYA) to Strong-Buy - MarketBeat
Hedge Fund Bets: Can Tenaya Therapeutics Inc lead its sector in growth2025 Market Sentiment & Precise Swing Trade Alerts - baoquankhu1.vn
Tenaya, Alnylam join in $1B+ cardio deal for novel genetic targets - BioWorld MedTech
Tenaya Therapeutics inks $1 billion-plus research deal with Alnylam - The Pharma Letter
Tenaya Therapeutics Stock Jumps After New Alnylam Deal - Sahm
TNYA Pulls Back After Hours Following Significant $1.13B Deal-Spurred Rally - Asianet Newsable
Tenaya Therapeutics Inc (TNYA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.82%
자본화:
|
볼륨(24시간):